| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
|
Medicine details |
|
| Medicine name | azacitidine (Vidaza®) |
| Formulation | 25 mg/ml powder for suspension for injection |
| Reference number | 2684 |
| Indication | Treatment of adult patients aged 65 years or older who are not eligible for haematopoietic stem cell transplantation with acute myeloid leukaemia with > 30% marrow blasts according to the WHO classification |
| Company | Celgene Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/11/2015 |
| NICE guidance | TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |